Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype

Infection and Immunity

Volumn 67, Issue 9, 1999, Pages 4744-4750

  Parad, Richard B ^a   Gerard, Craig J ^a   Zurakowski, David ^a   Nichols, David P ^b   Pier, Gerald B ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPSONIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC RESISTANCE; GENETIC VARIABILITY; GENOTYPE; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE STATUS; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OPSONIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SEX DIFFERENCE;

EID: 0032797445     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.9.4744-4750.1999     Document Type: Article

References (37)

1. Borgo, G., P. Gasparini, A. Bonizzato, G. Cabrini, G. Mastella, and P. F. Pignatti. 1993. Cystic fibrosis: the ΔF508 mutation does not lead to an exceptionally severe phenotype. A cohort study. Eur. J. Pediatr. 152:1006-1011.
2. Campbell, P. W., III, R. A. Parker, B. T. Roberts, M. R. Krishnamani, and J. A. Phillips III. 1992. Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the ΔF508 deletion. J. Pediatr. 120:261-264.
3. Campbell, P. W., III, J. A. Phillips III, M. R. Krishnamani, K. J. Maness, and T. A. Hazinski. 1991. Cystic fibrosis: relationship between clinical status and ΔF508 deletion. J. Pediatr. 118:239-241.
4. Chillon, M., T. Casals, B. Mercier, L. Bassas, W. Lissens, S. Silber, M. C. Romey, J. Ruizromero, C. Verlingue, M. Claustres, V. Nunes, C. Ferec, and X. Estivill. 1995. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 332:1475-1480.
5. Corey, M., L. Edwards, H. Levison, and M. Knowles. 1997. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J. Pediatr. 131:809-814.
6. Cystic Fibrosis Foundation. 1998. Patient registry 1997 annual data report. Cystic Fibrosis Foundation, Bethesda, Md.
7. Cystic Fibrosis Genetic Analysis Consortium. 1994. Population variation of common cystic fibrosis mutations. Hum. Mutat. 4:167-177.
8. Cystic Fibrosis Genotype-Phenotype Consortium. 1993. Correlation between genotype and phenotype in patients with cystic fibrosis. N. Engl. J. Med. 329:1308-1313.
9. Demko, C. A., P. J. Byard, and P. B. Davis. 1995. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J. Clin. Epidemiol. 48:1041-1049.
10. Ferrie, R. M., M. J. Schwarz, N. H. Robertson, S. Vaudin, M. Super, G. Malone, and S. Little. 1992. Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene. Am. J. Hum. Genet. 51:251-262.
11. Highsmith, W. E., L. H. Burch, Z. Zhou, J. C. Olsen, T. E. Boat, A. Spock, J. D. Gorvoy, L. Quittel, K. J. Friedman, L. M. Silverman, et al. 1994. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N. Engl. J. Med. 331:974-980.
12. Hosmer, D. W., and S. Lemeshow. 1989. Applied logistic regression, p. 13-19. John Wiley, New York, N.Y.
13. Jennrich, R. I., and M. D. Schluchter. 1986. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 42:805-820.
14. Johansen, H. K., M. Nir, N. Hoiby, C. Koch, and M. Schwartz. 1991. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet 337:631-634.
15. Kerem, B. S., J. M. Rommens, J. A. Buchanan, D. Markiewicz, T. K. Cox, A. Chakravarti, M. Buchwald, and L. C. Tsui. 1989. Identification of the cystic fibrosis gene - genetic analysis. Science 245:1073-1080.
16. Kerem, E., M. Corey, R. Gold, and H. Levison. 1990. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 116:714-719.
17. Kerem, E., M. Corey, B. S. Kerem, J. Rommens, D. Markiewicz, H. Levison, L. C. Tsui, and P. Durie. 1990. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation. N. Engl. J. Med. 323:1517-1522.
18. Khan, T. Z., J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso, and D. W. H. Riches. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:1075-1082.
19. Knudson, R. J., M. D. Lebowitz, C. J. Holberg, and B. Burrows. 1983. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am. Rev. Respir. Dis. 127:725-734.
20. Kristidis, P., D. Bozon, M. Corey, D. Markiewicz, J. Rommens, L. C. Tsui, and P. Durie. 1992. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am. J. Hum. Genet. 50:1178-1184.
21. Laird, N. M., and J. H. Ware. 1982. Random-effects models for longitudinal data. Biometrics 38:963-974.
22. Lester, L. A., J. Kraut, J. Lloyd-Still, T. Karrison, C. Mott, C. Billstrand, A. Lemke, and C. Ober. 1994. ΔF508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics 93:114-118.
23. Liechti-Gallati, S., I. Bonsall, N. Malik, V. Schneider, L. G. Kraemer, A. Ruedeberg, H. Moser, and R. Kraemer. 1992. Genotype/phenotype association in cystic fibrosis: analyses of the ΔF508, R553X, and 3905insT mutations. Pediatr. Res. 32:175-178.
24. Littell, R. C., G. A. Milliken, W. W. Stroup, and R. D. Wolfinger. 1996. SAS system for mixed models. SAS Institute Inc., Cary, N.C.
25. Mohon, R. T., J. S. Wagener, S. H. Abman, W. K. Seltzer, and F. J. Accurso. 1993. Relationship of genotype to early pulmonary function in infants with cystic fibrosis identified through neonatal screening. J. Pediatr. 122:550-555.
26. Pedersen, S. S., A. Kharazmi, F. Espersen, and N. Hoiby. 1990. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect. Immun. 58:3363-3368.
27. Pier, G. B., M. Grout, and T. S. Zaidi. 1997. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc. Natl. Acad. Sci. USA 94:12088-12093.
28. Pier, G. B., M. Grout, T. S. Zaidi, J. C. Olsen, L. G. Johnson, J. R. Yankaskas, and J. B. Goldberg. 1996. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271:64-67.
29. Pier, G. B., W. J. Matthews, and D. D. Eardley. 1983. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J. Infect. Dis. 147:494-503.
30. Pier, G. B., J. M. Saunders, P. Ames, M. S. Edwards, H. Auerbach, J. Goldfarb, D. P. Speert, and S. Hurwitch. 1987. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older, non-colonized cystic fibrosis patients. N. Engl. J. Med. 317:793-798.
31. Pier, G. B., G. J. Small, and H. B. Warren. 1990. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infection. Science 249:537-540.
32. Richards, B., J. Skoletsky, A. P. Shuber, R. Balfour, R. C. Stern, H. L. Dorkin, R. B. Parad, D. Witt, and K. W. Klinger. 1993. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum. Mol. Genet. 2:159-163.
33. Rosenstein, B. J. 1994. Genotype-phenotype correlations in cystic fibrosis. Lancet 343:746-747.
34. Santis, G., L. Osborne, R. A. Knight, and M. E. Hodson. 1990. Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. Lancet 336:1081-1084.
35. Santis, G., L. Osborne, R. A. Knight, and M. E. Hodson. 1990. Linked marker haplotypes and the delta F508 mutation in adults with mild pulmonary disease and cystic fibrosis. Lancet 335:1426-1429.
36. Sokal, R. R., and F. J. Rohlf. 1995. Biometry, 3rd ed., p. 730-734. W. H. Freeman, New York, N.Y.
37. Tosi, M. F., H. Zakem-Cloud, C. A. Demko, J. R. Schreiber, R. C. Stern, M. W. Konstan, and M. Berger. 1995. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J. Infect. Dis. 172:453-461.